<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754711</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO-2020-17</org_study_id>
    <nct_id>NCT04754711</nct_id>
  </id_info>
  <brief_title>Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition</brief_title>
  <acronym>NUTRIDREP</acronym>
  <official_title>Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is design to assess the effects of an increase in nutritional intake on the bone&#xD;
      mineral density of children with sickle cell disease, for 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Sickle cell disease is the most common inherited disease of the red blood cell&#xD;
&#xD;
        -  During sickle cell disease, the decrease in Bone Mineral Density (BMD) in children is&#xD;
           very common: 19 and 56% depending on the studies&#xD;
&#xD;
        -  children with sickle cell disease have an increase in resting energy expenditure of&#xD;
           15-20%&#xD;
&#xD;
        -  children with sickle cell disease have a significant decrease in muscle mass&#xD;
&#xD;
        -  there are no specific nutritional recommendations for sickle cell disease in children&#xD;
&#xD;
      Our main purpose is to assess the effects of an increase in nutritional intake on the bone&#xD;
      mineral density of children with sickle cell disease, for 12 months&#xD;
&#xD;
      Our secondary objectives are :&#xD;
&#xD;
        1. / Evaluate the effects of an increase in nutritional intake on: body composition, height&#xD;
           and weight growth, frequency of complications of sickle cell disease, school&#xD;
           absenteeism, cardiac function, cerebral vasculopathy, biological parameters follow-up,&#xD;
           and the relationship with the treatment started&#xD;
&#xD;
        2. / Creation of a sero-type blood bank for future research&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">February 23, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 23, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization of patients included in 2 groups&#xD;
Group 1: receiving an oral nutritional supplement to increase calorie intake by around 20%&#xD;
Group 2: &quot;controls&quot; receiving normal calorie intake without oral nutritional supplement Randomization will take into account age, gender and severity of disease in order to create two homogenous groups&#xD;
Monitoring by biphotonic absorptiometry, dietetic, clinical and biological&#xD;
Creation of a sero-type blood bank for the 2 groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in the mean Bone Mineral Density Z-score of the two randomized groups</measure>
    <time_frame>Baseline</time_frame>
    <description>The change in the mean Bone Mineral Density Z-score of the two randomized groups will be measured by biphotonic absorptiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in the mean Bone Mineral Density Z-score of the two randomized groups</measure>
    <time_frame>Month 12</time_frame>
    <description>The change in the mean Bone Mineral Density Z-score of the two randomized groups will be measured by biphotonic absorptiometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in body composition</measure>
    <time_frame>Month 12</time_frame>
    <description>Change in body composition expressed by lean mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with stature growth</measure>
    <time_frame>Month 12</time_frame>
    <description>abnormal stature growth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with weight growth</measure>
    <time_frame>Month 12</time_frame>
    <description>abnormal weight growth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with school absenteeism</measure>
    <time_frame>Month 12</time_frame>
    <description>The level of school absenteeism measured by means of a questionnaire of school absenteeism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of complications of sickle cell disease</measure>
    <time_frame>Month 12</time_frame>
    <description>Complications such as chronic pain, chronic and acute anemia, infections justifying hospitalization, multi visceral involvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence or not of impaired cardiac function and / or cardiac anatomy related to sickle cell disease</measure>
    <time_frame>Month 12</time_frame>
    <description>The presence or not of impaired cardiac function and / or cardiac anatomy related to sickle cell disease determined by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence or not of cerebral vasculopathy</measure>
    <time_frame>Month 12</time_frame>
    <description>The presence or not of a cerebral vasculopathy sought by transcranial Doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>an abnormal F-S-C hemoglobin level</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>an abnormal high serum Lactate DeHydrogenase value</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a low serum iron and ferritin value</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>an abnormal serum folate value</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>an abnormal C Reactive Protein value</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a deficiency in 25-OH vitamin D</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Osteoporosis</condition>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Group with oral nutritional supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: receiving an oral nutritional supplement to increase calorie intake by around 20%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group 2: &quot;controls&quot; receiving normal calorie intake without oral nutritional supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral Nutritional Supplement</intervention_name>
    <description>We will propose to the patients of group 1 several different oral nutritional supplements according to taste, and consistency of each child in order to optimize observance. Each of those different oral nutritional supplements will be adapted to the nutritional survey and the age of children without exceeding recommended intake of proteins, carbohydrates, lipids and micronutrients. Those patients will consume the Oral Nutritional Supplement during 12 months.</description>
    <arm_group_label>Group with oral nutritional supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Homozygous sickle cell disease SS, SC, SE, Sbeta + or Sbeta0&#xD;
&#xD;
          -  Ages 3 to 16 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Overweight at the start of the study&#xD;
&#xD;
          -  Child for whom one of the 2 parents refuses his child's participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georges DIMITROV, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR d'Orléans</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georges DIMITROV, Dr</last_name>
    <phone>+33238613390</phone>
    <email>georges.dimitrov@chr-orleans.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHR Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georges DIMITROV, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Schnog JB, Duits AJ, Muskiet FA, ten Cate H, Rojer RA, Brandjes DP. Sickle cell disease; a general overview. Neth J Med. 2004 Nov;62(10):364-74. Review.</citation>
    <PMID>15683091</PMID>
  </reference>
  <reference>
    <citation>Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010 Jun 3;115(22):4331-6. doi: 10.1182/blood-2010-01-251348. Epub 2010 Mar 16. Review.</citation>
    <PMID>20233970</PMID>
  </reference>
  <reference>
    <citation>Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010 Apr;38(4 Suppl):S512-21. doi: 10.1016/j.amepre.2009.12.022.</citation>
    <PMID>20331952</PMID>
  </reference>
  <reference>
    <citation>Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011 Dec;41(6 Suppl 4):S398-405. doi: 10.1016/j.amepre.2011.09.013.</citation>
    <PMID>22099364</PMID>
  </reference>
  <reference>
    <citation>Odièvre MH, Verger E, Silva-Pinto AC, Elion J. Pathophysiological insights in sickle cell disease. Indian J Med Res. 2011 Oct;134:532-7. Review.</citation>
    <PMID>22089617</PMID>
  </reference>
  <reference>
    <citation>Kanter J, Kruse-Jarres R. Management of sickle cell disease from childhood through adulthood. Blood Rev. 2013 Nov;27(6):279-87. doi: 10.1016/j.blre.2013.09.001. Epub 2013 Sep 19. Review.</citation>
    <PMID>24094945</PMID>
  </reference>
  <reference>
    <citation>Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010 Apr 29;115(17):3447-52. doi: 10.1182/blood-2009-07-233700. Epub 2010 Mar 1.</citation>
    <PMID>20194891</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle cell disease</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>Nutrition</keyword>
  <keyword>body composition</keyword>
  <keyword>Oral nutritional supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

